N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta relesase and reduces migration and invasiveness of human malignant glioma cells.
Extensive infiltration of normal brain tissue and suppression of anti-tumor immune surveillance mediated by molecules such as transforming growth factor-beta (TGF-beta) are key biological features that contribute to the malignant phenotype of human gliomas. Tranilast (N-[3,4-dimethoxycinnamoyl]-anthranilic acid) is an anti-allergic compound used clinically to control atopic and fibrotic disorders. These effects are attributed to the suppression of TGF-beta1 synthesis and interference with growth factor-mediated proliferation and migration of fibroblasts and vascular smooth muscle cells. Here, we show that tranilast inhibits DNA synthesis and proliferation of human malignant glioma cells and promotes p21 accumulation in the absence of cytotoxicity. Further, tranilast reduces the release of TGF-beta1 and TGF-beta2 by glioma cells and inhibits migration, chemotactic responses and invasiveness. These effects are not associated with a reduction of alpha(v)beta(3) integrin expression at the cell surface but appear to involve inhibition of matrix metalloproteinase-2 expression and activity. Neither the tranilast-mediated inhibition of proliferation nor the inhibition of migration was counteracted by supplementation with exogenous TGF-beta. Finally, tranilast administered orally inhibited the growth of experimental 9L rat gliomas and reduced expression of TGF-beta2 in vivo. We conclude that tranilast might be a useful therapeutic agent for the treatment of human malignant glioma because of a TGF-beta-independent abrogation of the malignant phenotype of proliferation, migration and invasiveness and because of the antagonism of TGF-beta-associated immunosuppression.
Platten
M
M
Laboratory of Molecular Neuro-Oncology, Department of Neurology, University of Tübingen, School of Medicine, Tübingen, Germany.
Wild-Bode
C
C
Wick
W
W
Leitlein
J
J
Dichgans
J
J
Weller
M
M
D016475:3T3 Cells; D000230:Adenocarcinoma; D000818:Animals; D001932:Brain Neoplasms / Q000473:pathology*; D002455:Cell Division / Q000187:drug effects; D002633:Chemotaxis / Q000187:drug effects*; D005260:Female; D005910:Glioma / Q000473:pathology*; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D020778:Matrix Metalloproteinase 2 / Q000235:genetics; D051379:Mice; D009361:Neoplasm Invasiveness / Q000517:prevention & control*; D009447:Neuroblastoma; D010051:Ovarian Neoplasms; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D019030:Receptors, Vitronectin / Q000502:physiology; D016212:Transforming Growth Factor beta / Q000378:metabolism*; D014407:Tumor Cells, Cultured; D062367:ortho-Aminobenzoates / Q000494:pharmacology*
D006634:Histamine H1 Antagonists; D010975:Platelet Aggregation Inhibitors; D019030:Receptors, Vitronectin; D016212:Transforming Growth Factor beta; D062367:ortho-Aminobenzoates; D020778:Matrix Metalloproteinase 2; C012293:tranilast